<p>Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.</p>

Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

Sign up to save your podcasts

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

More shows like GRACEcast Lung Cancer Video

GRACEcast Head and Neck Cancer Audio

GRACEcast Radiation Oncology Audio

GRACEcast Radiation Oncology Video

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Cancer 101 Audio

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video